Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial.

MLA

Rasmussen, Ida K. B., et al. “Liraglutide Reduces Cardiac Adipose Tissue in Type 2 Diabetes: A Secondary Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.” Diabetes, Obesity & Metabolism, vol. 23, no. 12, Dec. 2021, pp. 2651–59. EBSCOhost, https://doi.org/10.1111/dom.14516.

APA

Rasmussen, I. K. B., Zobel, E. H., Ripa, R. S., von Scholten, B. J., Curovic, V. R., Jensen, J. K., Kjaer, A., Hansen, T. W., & Rossing, P. (2021). Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial. Diabetes, Obesity & Metabolism, 23(12), 2651–2659. https://doi.org/10.1111/dom.14516

Chicago

Rasmussen, Ida K B, Emilie H Zobel, Rasmus S Ripa, Bernt J von Scholten, Viktor R Curovic, Jacob K Jensen, Andreas Kjaer, Tine W Hansen, and Peter Rossing. 2021. “Liraglutide Reduces Cardiac Adipose Tissue in Type 2 Diabetes: A Secondary Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.” Diabetes, Obesity & Metabolism 23 (12): 2651–59. doi:10.1111/dom.14516.